>>BOSTON--(BUSINESS WIRE)--March 30, 2004-- GlycoGenesys, Inc., (Nasdaq: GLGS - News), a biotechnology company developing carbohydrate-based drugs, will update its global patent strategy for GCS-100 in a presentation to be made later today at the fourth annual European C21 Bioventures Conference in London. GlycoGenesys is continuing development of GCS-100 for major foreign markets.
The Company plans on utilizing already issued foreign patents, as well as, a recently filed provisional patent application, owned exclusively by GlycoGenesys, Inc., that covers the new formulation of GCS-100, which the Company will pursue in both the U.S. and major foreign markets including but not limited to Europe, China, Israel, Japan and Brazil. The Company has intentionally relinquished certain applications for modified pectin material in Europe, China, Israel, Japan, Brazil and Canada licensed to the Company by David Platt because prior art prevented the issuance of these applications. Current Intellectual Property For GCS-100
The Company owns, or is the exclusive licensee of, all of its intellectual property. This intellectual property includes 13 issued US patents that have expiration dates ranging from 2013 to 2022; five of these 13 patents relate to GCS-100. The intellectual property also includes seven foreign patents having expiration dates ranging from 2015 to 2017. Five of these seven foreign patents relate to GCS-100. The Company's intellectual property further includes 12 pending US patent applications, of which 11 relate to GCS-100; and 41pending foreign patent applications of which 30 relate to GCS-100. As the Company develops GCS-100 further, it expects to discover more about its characteristics and manufacturing, for which it plans to file additional patent applications. The Company is continually evaluating its technologies to determine whether to make further patent filings. <<
snip
Cheers, Tuck |
